- Home
- IMUX vs DERM Comparison
IMUX vs DERM Comparison
Compare IMUX & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- DERM
- Stock Information
- Founded
- IMUX 2016
- DERM 2014
- Country
- IMUX United States
- DERM United States
- Employees
- IMUX N/A
- DERM N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- DERM Health Care
- Exchange
- IMUX Nasdaq
- DERM Nasdaq
- Market Cap
- IMUX 102.2M
- DERM N/A
- IPO Year
- IMUX N/A
- DERM 2021
- Fundamental
- Price
- IMUX $1.09
- DERM $5.89
- Analyst Decision
- IMUX Strong Buy
- DERM Strong Buy
- Analyst Count
- IMUX 7
- DERM 2
- Target Price
- IMUX $12.67
- DERM $10.00
- AVG Volume (30 Days)
- IMUX 555.7K
- DERM 61.2K
- Earning Date
- IMUX 05-07-2025
- DERM 03-26-2025
- Dividend Yield
- IMUX N/A
- DERM N/A
- EPS Growth
- IMUX N/A
- DERM N/A
- EPS
- IMUX N/A
- DERM N/A
- Revenue
- IMUX N/A
- DERM $56,134,000.00
- Revenue This Year
- IMUX N/A
- DERM N/A
- Revenue Next Year
- IMUX N/A
- DERM $36.49
- P/E Ratio
- IMUX N/A
- DERM N/A
- Revenue Growth
- IMUX N/A
- DERM N/A
- 52 Week Low
- IMUX $0.92
- DERM $3.20
- 52 Week High
- IMUX $2.11
- DERM $6.89
- Technical
- Relative Strength Index (RSI)
- IMUX 46.81
- DERM 55.75
- Support Level
- IMUX $1.18
- DERM $5.51
- Resistance Level
- IMUX $1.28
- DERM $6.84
- Average True Range (ATR)
- IMUX 0.07
- DERM 0.44
- MACD
- IMUX -0.00
- DERM 0.03
- Stochastic Oscillator
- IMUX 6.00
- DERM 45.66
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.